CD532

CD532 is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 also can directly interact with AURKA and induces a global conformational shift. CD532 can be used for the research of cancer[1][2].

Product Specifications

CAS Number

[1639009-81-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Aurora Kinase

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cd532.html

Purity

98.86

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

FC(F)(F)C1=CC=CC(NC(NC2=CC=C(NC3=NC=CC(NC4=NNC(C5CCCC5)=C4)=N3)C=C2)=O)=C1

Molecular Formula

C26H25F3N8O

Molecular Weight

522.52

Precautions

H302, H315, H319, H335

References & Citations

[1]Gustafson WC, et, al. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell. 2014 Sep 8;26 (3) :414-427.|[2]Lee JK, et, al. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell. 2016 Apr 11;29 (4) :536-547.